A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I–III hepatocellular carcinoma

A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I–III hepatocellular carcinoma

Background: Hepatocellular carcinoma (HCC) is a lethal disease with high relapse and dismal survival rates. Alternative splicing (AS) plays a crucial role in tumor progression. Herein, we aim to integratedly analyze the relapse-associated AS events and construct a signature predicting tumor relapse...

Full description

Bibliographic Details
Main Authors: Xu-Xiao Chen, Bao-Hua Zhang, Yan-Cen Lu, Zi-Qiang Li, Cong-Yan Chen, Yu-Chen Yang, Yong-Jun Chen, Di Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
alternative splicing
tumor relapse
prognosis
immunity
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.939912/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.939912/full

Similar Items